Aspirin

International hub for pharmaceutical tech

Retrieved on: 
onsdag, oktober 19, 2022
Genetics, Airea D. Matthews, Medicine, RNA transfection, Bayer, Aspirin, Workforce, Saxony-Anhalt, Vaccine, IMG, Patient, Research, Park, COVID-19, Center of excellence, Leipzig/Halle Airport, EXPO, Patent, WFS, Map, Center, Tablet, Capsule, Saluta Rocks

The "Airea" covers the entire pharmaceutical value chain, from research and development to production, and from marketing to logistics and service.

Key Points: 
  • The "Airea" covers the entire pharmaceutical value chain, from research and development to production, and from marketing to logistics and service.
  • The highly efficient, ultra-modern airport at Leipzig/Halle also has CEIV Pharma certification and can handle temperature- and time-critical pharmaceutical shipments such as vaccines around the clock.
  • The airport offers an international distribution network specifically geared to vaccine and medicine production in Europe, Africa, and the Middle East.
  • You can find more information and articles about the pharmaceutical mecca that is Saxony-Anhalt here .

Arjuna Natural: Rhuleave-K® Demonstrates Significant Pain Relief at Half the Dose

Retrieved on: 
tisdag, oktober 18, 2022
NSF, ISO, Exertion, McGill, Aspirin, Head, Turmeric, Specialization, GMP, Neck, Person, Health, AKBA, Research, Arjuna, Pain management, Medicine, Injury, NRS, Certification, Trial of the century, Analgesic, Exercise, MD, Doctor of Philosophy, Pharmacokinetics, Pain, Lists of diseases, Journal, Headache, Frankincense, Numerical, PRS, Dietary supplement

KOCHI, India, Oct. 18, 2022 /PRNewswire/ -- Results of a third clinical study reveal that Arjuna Natural Pvt. Ltd.'s Rhuleave-K® is also effective in pain relief at a dosage 50% that of the previous two studies. The blend of pure extracts of frankincense (Boswellia serrata) and turmeric (Curcuma longa) already was recognized in the first studies as providing relief of acute musculoskeletal pain following exercise, demonstrating a strong cumulative pain relief effect at 1,000mg. In response to the impressive results of the current study, the researchers note that it was encouraging to find that Rhuleave-K® works well even at 500mg.

Key Points: 
  • New study demonstrates lower dose of botanical blend provides quick pain relief.
  • Ltd.'s Rhuleave-K is also effective in pain relief at a dosage 50% that of the previous two studies.
  • The primary outcome was the sum of pain intensity difference at 6 hours, as evaluated by the Numerical Rating Scale (NRS), and total pain relief (TOTPAR6) evaluated by categorical pain relief scale (PRS) every 30 minutes over 6 hours.
  • Results showed a significant decrease (62%) in pain intensity for Rhuleave-K, with total pain relief 84% better than with the placebo.

Global Aspirin Market Report 2022: Growing Demand for Branded Generics to Boost Sector - ResearchAndMarkets.com

Retrieved on: 
tisdag, oktober 4, 2022
Health, Pharmaceutical, Marketing, Stroke, Aspirin, Degenerative disease, Statistics, Industry, Prevalence, Life, Analgesic, World Health Organization, CAGR, NIH, Pain, FDA, World, Headache, Fever, Medicine, Child, Nervous system, API, USFDA, Bayer, United Kingdom, 2000 Goody's Body Pain 500, Cardiology, Myalgia, Adhesive, Pharmaceutical industry

The "Global Aspirin Market - Forecasts from 2022 to 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Aspirin Market - Forecasts from 2022 to 2027" report has been added to ResearchAndMarkets.com's offering.
  • The global aspirin market size is estimated to augment at a CAGR of 2.40%, increasing from US$2.167 billion in 2020 to reach US$2.558 billion by 2027.
  • The growing demand for branded generics will continue to propagate market growth during the forecast period.
  • The prevalence of headaches worldwide will fuel the market demand for analgesics, further augmenting the market growth during the forecast period.

Galderma and National Breast Cancer Foundation Announce Continued Partnership to Launch Campaign Elevating Skin Stories of Breast Cancer Survivors

Retrieved on: 
måndag, oktober 3, 2022
Lip, History, Toxin (comics), Anaphylaxis, Lists of diseases, Safety, Pimple, Warfarin, Skin discoloration, Allergy, Swelling, Vitamin, Coagulopathy, Cheek, Victory Unintentional, Myasthenia gravis, Skin, Bleeding, Face, Rash, Upper respiratory tract infection, Recurrence, Headache, Skin infection, Lidocaine, Human, Patient, Severe cognitive impairment, Infection, Blood, Nausea, Bruise, ALS, Inflammation, Muscle, Amyotrophic lateral sclerosis, Red, Medication, Restylane, Aspirin, Muscle weakness, Nose, Tenderness, Wound, Multimedia, Pain, FDA, Herbal, Cyst, Vascular occlusion, Risk, Scar, Bacteria, Hypertrophic scar, Stroke, Sculptra, Catherine Disher, Infarction, Death, Hyaluronic acid, Eyebrow, Laser, Galderma, Use, Cosmetics, Canning, Birth control, Dietary supplement, Pharmaceutical industry, Medicine, Tissue paper, Botulinum toxin

These effects could make it unsafe for you to drive a car, operate machinery, or do other dangerous activities.

Key Points: 
  • These effects could make it unsafe for you to drive a car, operate machinery, or do other dangerous activities.
  • Tell your doctor about all the medicines you take, including prescription and nonprescription medicines, vitamins and herbal and other natural products.
  • Use at the site of skin sores, cysts, pimples, rashes, hives or infection should be postponed until healing is complete.
  • Other side effects may include small lumps under the skin that are sometimes noticeable when pressing on the treated area.

People Science™ and Sen-Jam Pharmaceutical partner to develop people-forward tools to study inflammation, pain, and opioid withdrawal symptoms in the real world

Retrieved on: 
torsdag, september 22, 2022
People, Adoption, Health, Inflammation, Therapy, Time, LOS, MD, Quarantine, Knowledge, Partnership, Industry, Patient, MS, Attention, Aspirin, Thought, Technology, Pain, Quality of life, Solution, Doctor of Philosophy, Drug development, Indian Medical Association, American Medical Association, Research, Communication, All India Peoples Science Network, Opioid use disorder, Medicine, Pharmaceutical industry, Science, Pharmacist

LOS ANGELES and HUNTINGTON, N.Y., Sept. 22, 2022 /PRNewswire/ -- People Science™, a direct-to-consumer scientific research company providing a scaled R&D platform for alternative medicines, and Sen-Jam Pharmaceutical, a drug development company creating novel solutions for pain and inflammation, announce today a partnership to develop tools for healthcare providers and their patients to track, monitor, and understand the effects of treatments on their health in the real world setting. Using a data-driven and people-forward approach, People Science will develop protocols and workflows, designed in collaboration with experts in opioid use disorder and inflammatory disease states. People Science's proprietary software technology CHLOE™, the Consumer Health Learning and Organizing Ecosystem, will enable both the healthcare providers and their patients to track symptoms, outcomes, quality of life, and the response to various therapies and approaches. CHLOE is a highly customizable, modular software technology that combines a consumer-facing mobile app with a rigorous high-quality clinical research platform. People Science will then work with engaged clinicians and their patients to prototype the useability and usefulness of this tool in everyday practice in the clinics and at home.

Key Points: 
  • Using a data-driven and people-forward approach, People Science will develop protocols and workflows, designed in collaboration with experts in opioid use disorder and inflammatory disease states.
  • CHLOE is a highly customizable, modular software technology that combines a consumer-facing mobile app with a rigorous high-quality clinical research platform.
  • "The number one reason a person cannot release themselves from the grip of opioid use is the harrowing withdrawal symptoms.
  • Sen-Jam repurposes small molecules to develop novel therapeutics for large unmet needs with a focus on improving clinical outcomes.

JENNIFER DEAN BRINGS AN OPERATIONS MINDSET TO CORNERSTONE'S CFO ROLE

Retrieved on: 
onsdag, september 21, 2022
Fire, Autoneum, Culture, CFO, Fruit, Northwood University, Organization, Life, Henkel, Cornerstone, Aspirin, MBA, Chemical industry, CCO, Grupo Antolin, Multimedia, Nightclub, Management

TOLEDO, Ohio, Sept. 21, 2022 /PRNewswire/ --Basketball fans in Rochester, Michigan, who cheered young Jennifer Dean setting brutal picks, rebounding with intensity and playing defense like her life depended on it wouldn't be surprised to know she's still sparking competitive fires in her teammates. While they wear golf shirts instead of jerseys, the team at the Cornerstone Consulting Organization is benefiting from Jennifer's gritty resilience, no matter the challenge. CCO's clients are equally grateful for her insights.

Key Points: 
  • Jennifer Dean joins the team at Cornerstone Consulting Organization as CFO, with over 20 years experience in finance and operations.
  • "We knew Jennifer would be a perfect fit for our culture here at Cornerstone," said Bill Currence, CCO's President & Managing Partner.
  • "I can't help that I tackle situations with a coach's mindset," said Dean, who also holds an MBA from Northwood University.
  • Fortunately for Dean, her competitive spirit no longer leads to nights spent nursing floor burns and bruises with ice packs and aspirin.

The Worldwide Non-steroidal Anti-inflammatory Drugs Industry is Expected to Reach $25.5 Billion by 2028 - ResearchAndMarkets.com

Retrieved on: 
måndag, september 19, 2022
Health, Other Health, Headache, Dizziness, Enzyme, Inflammation, Allergy, Civilization, Incidence, Prevalence, Nonsteroidal anti-inflammatory drug, Ulcerative colitis, Population, Time-invariant system, Growth, NSAID, Drug tolerance, Analgesic, Person, Aspirin, Naproxen, Ibuprofen, COX-1, History, OTC, Pain, Migraine, Injury, Disorder, CDC, Toothache, Dysmenorrhea, Abdominal pain, Pain scale, Chronic pain, Birth control, Poultry

Inflammation is caused by the COX-1 and COX-2 enzymes that are inhibited by non-steroidal anti-inflammatory medications (NSAIDs).

Key Points: 
  • Inflammation is caused by the COX-1 and COX-2 enzymes that are inhibited by non-steroidal anti-inflammatory medications (NSAIDs).
  • The market for non-steroidal anti-inflammatory medications (NSAIDs) is expanding as a result of a number of causes, including the growing incidence of chronic pain worldwide and an ageing population.
  • For instance, the CDC estimates that in the United States, about 20,4% of adults experienced chronic pain in 2019.
  • Compared to Hispanic, non-Hispanic Asian, and non-Hispanic black individuals, non-Hispanic whites had the highest prevalence of chronic pain.

Baseball Legend John Smoltz Featured on PLx Pharma’s Social Channels

Retrieved on: 
måndag, september 12, 2022
OBI Pharma, Inc., Twitter, Risk, Pain Awareness Month, FDA, Food, PLX, ACHES, Corporate communication, LinkedIn, Company, Pains, Capsule, API, Aspirin, CEO, Pain, NASDAQ, Pain management, Golf, GLOBE, Supermarket, Awareness, Pharma, Absorption, Patent, Food and Drug Administration, Stomach, Generic drug, Facebook

From baseball to golf, I dont want aches and pains to slow me down, said Smoltz.

Key Points: 
  • From baseball to golf, I dont want aches and pains to slow me down, said Smoltz.
  • We are very excited to launch our new Facebook campaign with John, a current VAZALORE user and believer in its many benefits, said Natasha Giordano, President & CEO of PLx Pharma.
  • PLx Pharmas VAZALORE is the first and only U.S. Food and Drug Administration (FDA)-approved liquid-filled aspirin capsule.
  • To learn more about PLx Pharma Inc. and its pipeline, please visit www.plxpharma.com and follow us on LinkedIn and Twitter .

Boston Scientific Receives FDA Approval for Expanded Labeling of WATCHMAN FLX™ LAAC Device for Dual Anti-Platelet Therapy as Post-Procedural Medication Option

Retrieved on: 
tisdag, september 6, 2022
Security (finance), Technology, LAA, Securities Exchange Act of 1934, NYSE, Safety, BSX, Securities Act of 1933, Warfarin, Boston Scientific, Food and Drug Administration, Time, Exercise, DAPT, Boston, Risk, Left atrial appendage occlusion, NCDR, CT, Drug Quality and Security Act, Food, Physician, American College, Science, Forward-looking statement, NVAF, FLX, U.S. Securities and Exchange Commission, Aspirin, OAC, Intention, ACCF, FDA, Twitter, Ventricular fibrillation, Intellectual property, Annual report, LAAC, Health, Life, Patient, Pharmaceutical industry, Medical device, Part Two, Facebook, Amulet

MARLBOROUGH, Mass., Sept. 6, 2022 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval to expand the instructions for use labeling for the current-generation WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device to include a 45-day dual anti-platelet therapy (DAPT) option as an alternative to 45-day oral anticoagulation (OAC) plus aspirin for post-procedural treatment of patients with non-valvular atrial fibrillation (NVAF).

Key Points: 
  • "This significant step forward is supported by the robust safety and efficacy profile demonstrated by both the legacy WATCHMAN and current-generation WATCHMAN FLX technologies."
  • The labeling in Europe has included the choice of either OAC or a DAPT post-procedural drug regimen for WATCHMAN technology since 2017.
  • Ongoing studies with the WATCHMAN FLX device include the CHAMPION-AF and OPTION clinical trials to evaluate use of the device for broader patient populations with NVAF.
  • Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world.

The Polypill Reduces Cardiovascular Mortality by 33% in Patients Treated After Myocardial Infarction

Retrieved on: 
fredag, augusti 26, 2022
Research, Clinical Trials, Cardiology, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, Mortality, Ramipril, European Society of Cardiology, Ferrer, Spanish National Center for Biotechnology, Death, The New England Journal of Medicine, Mount Sinai Hospital, Incidence, NEJM, Business development, Myocardial infarction, Union, ACE, Multimedia, Aspirin, Atorvastatin, FOCUS, CNIC, Hypertension, History, Population, Mount Sinai Hospital (Manhattan), ESC, Diabetes, Risk, Woman, Tobacco smoking, Czech Republic, Patient, Pharmaceutical industry, Medical device

The polypill reduces mortality from cardiovascular causes in this population by 33%.

Key Points: 
  • The polypill reduces mortality from cardiovascular causes in this population by 33%.
  • SECURE included 2499 patients from 7 European countries (Spain, Italy, Germany, the Czech Republic, France, Poland, and Hungary) recovering after a myocardial infarction.
  • The SECURE trial analyzed the incidence of four major cardiovascular events: death from cardiovascular causes, non-fatal myocardial infarction, non-fatal stroke, and emergency coronary revascularization (the restoration of blood flow through a blocked coronary artery).
  • The study followed patients for an average of 3 years and produced conclusive results: patients taking the polypill had a 24% lower risk of these four events than patients taking the three drugs separately.